Integrated Training in Pharmacological Sciences

描述（申请人提供）：西奈山药理学综合培训项目旨在提供严格的多学科博士前研究教育，培养项目毕业生加强新药发现的能力。不同的方法将包括确定新的靶点、新的筛选或结构信息，为药物设计提供信息，预测/证明药物安全性及其副作用的方法，以及预测已经批准使用的药物重新利用机会的方法。对具有这种技能的科学家的需求是显而易见的，因为我们面临着：缺乏新的治疗方法；对太多疾病缺乏有效的治疗选择；不同个体对某种药物的反应范围之广令人费解；需要创新的治疗方案，包括药物组合和克服耐药性的新策略。该培训计划将使学员参与计算和系统生物学应用于“组学”和其他大型数据集分析，为新的可测试疾病模型提供信息，并揭示潜在的新治疗策略。这些方法将成为一些受训者的项目领域，而其他受训者则采用结构或化学方法来开发有关新目标的信息或为新药的设计提供信息。一些受训者将侧重于开发可应用于疾病或治疗相关网络分析的新计算工具，而另一些受训者将侧重于特定的生物医学问题。培训计划培养这些不同专业的受训者利用彼此专业知识的协作优势的能力。建议的每年最多12名学员将从培训计划中获得2-3年的支持，从博士和医学博士/博士培训的第一个或前两个学年开始。学生,分别。博士学位通常在入学后5.5年内完成。这个由42名来自11个不同院系的教师组成的高度协作的团队，包括基础科学和临床科学。它包括来自药理学和系统治疗学系的17名教员和来自结构和化学生物学系的5名教员，这是全校实验治疗研究所（ETI）的主要贡献部门。ETI为研究小组提供了获取新兴药物开发工具的途径。大多数受训者在研究生院的疾病和治疗学系统生物学培训领域攻读博士学位课程，大多数参与教学的教师都为教学工作做出了贡献。该计划的毕业生将在一系列令人满意的学术和制药环境以及其他途径中使用他们的培训，他们将从博士前培训中获得的特殊技能运用到这些培训中。

DESCRIPTION (provided by applicant): The Integrated Training in Pharmacological Sciences Program at Mount Sinai aims to provide rigorous multi- disciplinary pre-doctoral research education that fosters the ability of Program graduates to enhance discovery of new drugs. The diverse approaches will include identification of new targets, new screens or structural information to inform drug design, methods for prediction/demonstration of the safety of a drug and its side effects, and methods to predict opportunities for re-purposing drugs that have already been in approved use. The need for scientists with such skills is clear since we face: a paucity of new therapeutics in the pipeline; a lack of effective therapeutic options for too many diseases; a perplexingly wide range of responses among different individuals to a particular drug; and a need for innovative therapeutic options that include drug combinations and new strategies to overcome drug resistance. The Training Program will engage trainees in computational and systems biological applications to the "omics" and other large data set analyses that inform new testable models of disease and reveal potential new therapeutic strategies. These approaches will become the project areas for some trainees, while others pursue structural or chemical approaches to develop information about new targets or to inform the design of new drugs. Some trainees will focus on developing the new computational tools that can be applied to disease- or therapeutic-related network analyses, while others focus on particular biomedical problems. The Training Program fosters the ability of trainees with these diverse specializations to take collaborative advantage of each other's expertise. The proposed group of up to 12 trainees per year will typically receive support from the Training Program for 2-3 years, starting after the first or first two training years for Ph.D. and MD/Ph.D. students, respectively. The Ph.D. degree is typically completed within 5.5 years from matriculation. The highly collaborative group of 42 participating faculty members comes from 11 different departments, both basic science and clinical. It includes 17 faculty members from the Pharmacology and Systems Therapeutics Department and 5 from the Structural and Chemical Biology Department, the major contributing departments to the school-wide Experimental Therapeutics Institute (ETI). ETI provides research groups with access to emerging tools for drug development. Most trainees pursue their Ph.D. coursework in the Systems Biology of Disease and Therapeutics training area of the Graduate School and most participating faculty contribute to the teaching efforts. Graduates of the Program, use their training in a gratifying array of academic and pharmaceutical settings and other paths, in which they apply the special skill sets they bring from their pre-doctoral training.